FDA Approves Avelumab/Axitinib for Frontline RCC

May 15, 2019 – The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma. The approval is based on results from the pivotal phase III JAVELIN Renal 101 trial, which showed that the combination was associated with a 31% reduction in disease progression or death compared with sunitinib in an intent-to-treat population (ITT) of patients with treatment-naïve advanced RCC, regardless of … (leggi tutto)